Evidence map›Paper›PMID 34998996›Full record

ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2022

Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease.

Sarah Frey, Reezwana Chowdhury, Caoilfhionn M Connolly, William A Werbel, Dorry L Segev, Alyssa M Parian, IBD GROUP

Open access · greenAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sarah FreyDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Reezwana ChowdhuryDivision of Gastroenterology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Caoilfhionn M ConnollyDivision of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
William A WerbelDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Dorry L SegevDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland.
Alyssa M ParianDivision of Gastroenterology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: aparian1@Jhmi.edu.
IBD GROUPDivision of Gastroenterology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Johns Hopkins University · US

Funding

Clinical and Laboratory Research Training for Gastrointestinal SurgeonsT32DK007713 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI DAVID J HACKAM · 1996 to 2026
$5.2M
Patient Oriented Research in Solid Organ TransplantationK24AI144954 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SEGEV, DORRY L. · 2020 to 2024
$956k
Aggressive Organ Procurement Organization Report Cards to Safely Increase Kidney TransplantationF32DK124941 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI BOYARSKY, BRIAN · 2020 to 2020
$81k
NIAID NIH HHS K24 AI144954NIDDK NIH HHS F32 DK124941NIDDK NIH HHS T32 DK007713
6 · The paper itself

Abstract

Patients with inflammatory bowel disease (IBD) are recommended to receive vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), regardless of their immunosuppression status. Immunosuppressive medications represent a mainstay of therapy in moderate to severe IBD; however, their impact on the SARS-CoV-2 vaccine response remains unclear. Studies thus far have shown that patients with IBD on various therapies had detectable antibody responses after standard vaccinations.

Indexed as

COVID-19Inflammatory Bowel DiseasesViral VaccinesAntibody FormationCOVID-19 VaccinesHumansRNA, MessengerSARS-CoV-2VaccinationCOVID-19 VaccinesRNA, MessengerViral Vaccines

Identifiers

PMID34998996
PMCPMC8732901
OpenAlexW4206183162

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.